QY Research released a latest market research report on the global T-Cell & NK-Cell Engaging Bispecific Antibodies market, which is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global T-Cell & NK-Cell Engaging Bispecific Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
Summary
In 2021, the global T-Cell & NK-Cell Engaging Bispecific Antibodies market size was US$ 472 million and it is expected to reach US$ 5072 million by the end of 2028, with a CAGR of 40.82% during 2021-2028. In Japan the T-Cell & NK-Cell Engaging Bispecific Antibodies market size is expected to grow from US$ 1.88 million in 2021 to US$ 173.15 million by 2028, at a CAGR of 99.82% during the forecast period.
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Scope and Market Size
T-Cell & NK-Cell Engaging Bispecific Antibodies market is segmented by players, region (country), by Type, and By Application. Players, stakeholders, and other participants in the global T-Cell & NK-Cell Engaging Bispecific Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and By Application in terms of revenue and forecast for the period 2017-2028.
For More Information About This Report, Please Enter:
https://us.qyresearch.com/reports/354053/t-cell-nk-cell-engaging-bispecific-antibodies
By Company
Amgen
Immunocore
Johnson & Johnson
Roche
Company Five
AbbVie
MacroGenics
Regeneron
Astellas Pharma
GEMoaB Monoclonals
Molecular Partners
AstraZeneca
Merck
Eli Lilly
IGM Biosciences
Novartis
CytomX Therapeutics
Lava Therapeutics
Takeda
Segment by Type
T Cell Engagers
NK Cell Engagers
Segment by Application
Hematological Cancers
Solid Tumors
The report on the T-Cell & NK-Cell Engaging Bispecific Antibodies market covers the following region (country) analysis:
By Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
Southeast Asia
Australia
India
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe
South America
Brazil
Rest of South America
Middle East & Africa
Middle East
Africa
The Goal of the Report
- To study and analyze the global T-Cell & NK-Cell Engaging Bispecific Antibodiesconsumption (value & volume) by key regions/countries, type and application, history data from 2017 to 2022, and forecast to 2028.
- To understand the structure of T-Cell & NK-Cell Engaging Bispecific Antibodiesmarket by identifying its various subsegments.
- Focuses on the key global T-Cell & NK-Cell Engaging Bispecific Antibodiesmanufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
- To analyze the T-Cell & NK-Cell Engaging Bispecific Antibodieswith respect to individual growth trends, prospects, and their contribution to the total market.
- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges, and risks).
- To project the consumption of T-Cell & NK-Cell Engaging Bispecific Antibodiessubmarkets, with respect to key regions (along with their respective key countries).
- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
- To strategically profile the key players and comprehensively analyze their growth strategies.
Target Audience
> T-Cell & NK-Cell Engaging Bispecific Antibodies companies
> Research organizations
> Government Organizations
> Research/Consultancy firms
Table of Contents
1 REPORT OVERVIEW 1
1.1 Study Scope 1
1.2 Market Analysis by Type 2
1.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 2
1.2.2 T Cell Engagers 3
1.2.3 NK Cell Engagers 4
1.3 Market by Application 5
1.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application: 2017 VS 2021 VS 2028 5
1.3.2 Hematological Cancers 7
1.3.3 Solid Tumors 7
1.4 Study Objectives 7
1.5 Years Considered 8
2 GLOBAL GROWTH TRENDS 9
2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Perspective (2017-2028) 9
2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Growth Trends by Regions 10
2.2.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions: 2017 VS 2021 VS 2028 10
2.2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Regions (2017-2022) 12
2.2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Regions (2023-2028) 12
2.2.4 Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share in Global Market 2017-2028 14
2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Dynamic 14
2.3.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Trends 14
2.3.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Drivers 15
2.3.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges 16
2.3.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints 16
3 COMPETITION LANDSCAPE BY KEY PLAYERS 17
3.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Revenue 17
3.1.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Revenue (2017-2022) 17
3.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Players (2017-2022) 17
3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) 18
3.3 Players Covered: Ranking by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue 19
3.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio 19
3.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio (CR5 and HHI) 19
3.4.2 Global Top 2 Companies by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue in 2021 20
3.5 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Players Head office and Area Served 20
3.6 Key Players T-Cell & NK-Cell Engaging Bispecific Antibodies Product Solution and Service 21
3.7 Date of Enter into T-Cell & NK-Cell Engaging Bispecific Antibodies Market 21
3.8 Mergers & Acquisitions, Expansion Plans 22
4 T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES BREAKDOWN DATA BY TYPE 24
4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Type (2017-2022) 24
4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Type (2023-2028) 25
5 T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES BREAKDOWN DATA BY APPLICATION 26
5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Application (2017-2022) 26
5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Application (2023-2028) 27
6 NORTH AMERICA 28
6.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028) 28
6.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) 28
6.3 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) 29
6.4 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) 29
6.4.1 United States 30
6.4.2 Canada 31
6.4.3 Mexico 32
7 EUROPE 33
7.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028) 33
7.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) 33
7.3 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) 34
7.4 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) 34
7.4.1 Germany 36
7.4.2 France 37
7.4.3 U.K. 38
7.4.4 Italy 39
7.4.5 Russia 40
8 ASIA-PACIFIC 41
8.1 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028) 41
8.2 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) 41
8.3 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) 42
8.4 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region (2017-2022) 42
8.4.1 China 43
8.4.2 Japan 44
8.4.3 South Korea 45
8.4.4 Southeast Asia 45
8.4.5 India 46
9 SOUTH AMERICA 47
9.1 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028) 47
9.2 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) 47
9.3 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) 48
9.4 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) 48
9.4.1 Brazil 49
10 MIDDLE EAST & AFRICA 50
10.1 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028) 50
10.2 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) 50
10.3 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) 51
10.4 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) 51
10.4.1 Middle East 52
10.4.2 Africa 53
11 KEY PLAYERS PROFILES 54
11.1 Amgen 54
11.1.1 Amgen Company Details 54
11.1.2 Amgen Business Overview 54
11.1.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 55
11.1.4 Amgen Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022) 56
11.1.5 Amgen Recent Development 56
11.2 Immunocore 57
11.2.1 Immunocore Company Details 57
11.2.2 Immunocore Business Overview 58
11.2.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 58
11.2.4 Immunocore Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022) 59
11.2.5 Immunocore Recent Development 59
11.3 Johnson & Johnson 60
11.3.1 Johnson & Johnson Company Details 60
11.3.2 Johnson & Johnson Business Overview 60
11.3.3 Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 61
11.3.4 Johnson & Johnson Recent Development 62
11.4 Roche 62
11.4.1 Roche Company Details 62
11.4.2 Roche Business Overview 63
11.4.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 63
11.4.4 Roche Recent Development 64
11.5 Pfizer 65
11.5.1 Pfizer Company Details 65
11.5.2 Pfizer Business Overview 65
11.5.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 66
11.5.4 Pfizer Recent Development 66
11.6 AbbVie 66
11.6.1 AbbVie Company Details 66
11.6.2 AbbVie Business Overview 67
11.6.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 67
11.6.4 AbbVie Recent Development 68
11.7 MacroGenics 68
11.7.1 MacroGenics Company Details 68
11.7.2 MacroGenics Business Overview 69
11.7.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 69
11.7.4 MacroGenics Recent Development 69
11.8 Regeneron 70
11.8.1 Regeneron Company Details 70
11.8.2 Regeneron Business Overview 70
11.8.3 Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 70
11.8.4 Regeneron Recent Development 71
11.9 Astellas Pharma 71
11.9.1 Astellas Pharma Company Details 71
11.9.2 Astellas Pharma Business Overview 71
11.9.3 Astellas Pharma Recent Development 72
11.10 GEMoaB Monoclonals 72
11.10.1 GEMoaB Monoclonals Company Details 72
11.10.2 GEMoaB Monoclonals Business Overview 73
11.10.3 GEMoaB Monoclonals Recent Development 73
11.11 Molecular Partners 74
11.11.1 Molecular Partners Company Details 74
11.11.2 Molecular Partners Business Overview 74
11.11.3 Molecular Partners Recent Development 74
11.12 AstraZeneca 75
11.12.1 AstraZeneca Company Details 75
11.12.2 AstraZeneca Business Overview 75
11.12.3 AstraZeneca Recent Development 76
11.13 Merck 76
11.13.1 Merck Company Details 76
11.13.2 Merck Business Overview 76
11.13.3 Merck Recent Development 77
11.14 Eli Lilly 77
11.14.1 Eli Lilly Company Details 77
11.14.2 Eli Lilly Business Overview 78
11.14.3 Eli Lilly Recent Development 78
11.15 IGM Biosciences 79
11.15.1 IGM Biosciences Company Details 79
11.15.2 IGM Biosciences Business Overview 79
11.15.3 IGM Biosciences Recent Development 80
11.16 Novartis 80
11.16.1 Novartis Company Details 80
11.16.2 Novartis Business Overview 80
11.16.3 Novartis Recent Development 81
11.17 CytomX Therapeutics 81
11.17.1 CytomX Therapeutics Company Details 81
11.17.2 CytomX Therapeutics Business Overview 82
11.17.3 CytomX Therapeutics Recent Development 82
11.18 Lava Therapeutics 83
11.18.1 Lava Therapeutics Company Details 83
11.18.2 Lava Therapeutics Business Overview 83
11.18.3 Lava Therapeutics Recent Development 83
11.19 Takeda 84
11.19.1 Takeda Company Details 84
11.19.2 Takeda Business Overview 84
11.19.3 Takeda Recent Development 84
12 ANALYST’S VIEWPOINTS/CONCLUSIONS 86
13 APPENDIX 88
13.1 Research Methodology 88
13.1.1 Methodology/Research Approach 88
13.1.2 Data Source 91
13.2 Disclaimer 94
Access full Report Description, Table of Figure, Chart, FREE sample, etc. please click
https://us.qyresearch.com/reports/354053/t-cell-nk-cell-engaging-bispecific-antibodies
Any doubts and questions will be welcome.
Customization of the Report:
This report can be customized to meet the client’s requirements. Please contact with us ([email protected]), who will ensure that you get a report that suits your needs.
About Us:
QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 15 years’ experience and professional research team in various cities over the world，QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 59,000 clients across five continents. Let’s work closely with you and build a bold and better future.
Contact Us
QY Research
E-mail: [email protected]
Tel: +1-626-842-1666(US) +852-5808-0956 (HK)
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
Website: https://us.qyresearch.com